Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 16/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 11/20 | 0.56 |
| ▸ | MITF | O75030 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 2/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | SAE1 | Q9UBE0 | 2/20 | 0.54 |
| ▸ | UBA2 | Q9UBT2 | 2/20 | 0.54 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.54 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 2/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | THRB | P10828 | 1/20 | 0.51 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14689713 | 0.83 | DDR2 (0.60) | MAPTKDM4EPOLBHTT | |
| SCHEMBL17208706 | 0.83 | DDR1 (0.55) | MAPTKDM4EMITFPOLBRXFP1 | |
| SCHEMBL17208648 | 0.81 | EGFR (0.59) | MAPTKDM4E | |
| SCHEMBL17208652 | 0.80 | PIKFYVE (0.56) | — | |
| SCHEMBL17208620 | 0.79 | DDR1 (0.55) | MAPTHTTRXFP1 | |
| SCHEMBL13708193 | 0.79 | MAPT (0.64) | MAPTKDM4EMITFNPC1MAPK1 | |
| SCHEMBL17208707 | 0.76 | MAPT (0.47) | MAPTPOLBHTTRXFP1 | |
| SCHEMBL17208612 | 0.75 | MAPK14 (0.53) | — | |
| SCHEMBL1134930 | 0.74 | MAPT (0.48) | MAPTKDM4EMITFNPC1MAPK1 | |
| SCHEMBL12517070 | 0.74 | RET (0.42) | MAPTKDM4EHTTRXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9180127-B2 | Type II Raf kinase inhibitors | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2015-11-10 | — | — | US | disclosed |
| EP-2937345-A2 | Type II raf kinase inhibitors | Dana-Farber Cancer Institute, Inc. (US) | 2015-10-28 | — | — | EP | disclosed |